Text Size

Comparative Study of Latanoprost Drug Delivery Systems for Glaucoma Treatment and Their Interaction with the Tear Film Lipid Layer Models

Saija M.C.; Vazdar K.; Pajerski W.; Olżyńska A.; Daull P.; Garrigue J.-S.; Cwiklik L.


  • 2023
  • Molecular Pharmaceutics
View publication
  • Therapeutic Area

    Glaucoma

  • Technology

    Drug Delivery

  • Affiliations

    J. Heyrovský Institute of Physical Chemistry, Czech Academy of Sciences, Dolejškova 3, Prague, 18223, Czech Republic; Department of Physical and Macromolecular Chemistry, Faculty of Science, Charles University, Hlavova 8, Prague, 12800, Czech Republic; SANTEN SAS, Novagali Innovation Center, 1 rue Pierre Fontaine, Bâtiment Genavenir IV, Evry, F-91458 Cedex, France

Related Publications

Personality Traits Associated with Treatment Choice with an Explicit Statistical Prediction After an Explanation in a Negative Context: A Study in Patients with Glaucoma

Kodaka F.; Noro T.; Kishimoto N.; Kurosawa M.; Itoh Y.; Ogawa S.; Watanabe T.; Kubota M.; Hori K.; Shigeta M.; Nakano T.


Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: 2-year Results from a Randomized, Multicenter Study

Panarelli JF, Moster MR, Garcia-Feijoo J, Flowers BE, Baker ND, Barnebey HS, Grover DS, Khatana AK, Lee B, Nguyen T, Stiles MC, Sadruddin O, Khaw PT.


Omidenepag Isopropyl in Latanoprost Low/Non-Responders with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3, Non-Randomized, Two-Phase, Open-Label Study

Panarelli JF, Bowden EC, Tepedino ME, Odani-Kawabata N, Pei Z, McLaurin EB, Ropo A.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022